PCRX Q1 2025 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$971M

Q1 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$169M+1.1% YoY

Gross Profit

$135M79.7% margin

Operating Income

$2M1.2% margin

Net Income

$5M2.8% margin

EPS (Diluted)

$0.10

QoQ Revenue Growth

-9.8%

Cash Flow

Operating Cash Flow

$35M

Free Cash Flow

$27M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$788M

Stockholders' Equity

$799M

Cash & Equivalents

$284M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$169M	$167M	+1.1%
Gross Profit	$135M	$120M	+12.5%
Operating Income	$2M	$13M	-84.9%
Net Income	$5M	$9M	-46.4%

Revenue Segments

Product

$168M51%

EXPAREL

$137M41%

ZILRETTA

$23M7%

Bupivacaine Liposome Injectable Suspension

$3M1%